Welcome to our dedicated page for Chiron Real Estate SEC filings (Ticker: GMRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Chiron Real Estate's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Chiron Real Estate's regulatory disclosures and financial reporting.
Global Medical REIT Inc. (GMRE) filed its Q3 2025 report, showing steady rent growth but a quarterly loss driven by an impairment. Rental revenue was $37,036 in the quarter and total revenue was $37,229. Expenses rose on depreciation and interest, and the Company recorded a $6,281 impairment, resulting in net loss attributable to common stockholders of $6,001, or $0.45 per share.
For the nine months, total revenue reached $109,816 with operating cash flow of $51,977. GMRE acquired a five‑property medical real estate portfolio and completed five dispositions across Kansas, Oregon, Florida, Tennessee, and Illinois. The Company executed a 1‑for‑5 reverse stock split effective September 19, 2025, and reported 13,407,358 common shares outstanding as of November 3, 2025.
Balance sheet highlights include total assets of $1,273,238 and Credit Facility borrowings of $711,700 gross (Revolver $211,700, Term Loans $500,000). Subsequent to quarter end, on October 8, 2025 GMRE amended and restated its Credit Facility, extending the Revolver to October 2029, splitting Term Loan A into tranches maturing in 2029, 2030, and 2031, and removing the 0.10% SOFR spread adjustment.
Global Medical REIT Inc. (GMRE) furnished its Third Quarter 2025 results materials. On November 4, 2025, the company announced its financial position as of September 30, 2025 and operating results for the three and nine months ended September 30, 2025. The earnings release (Exhibit 99.1) and earnings supplemental (Exhibit 99.2) were posted to its website and furnished with this report.
The materials are furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference into other filings.
Global Medical REIT Inc. amended its credit facilities to extend maturities and reprice a spread adjustment. The $400M revolver maturity is extended to October 2029 with two six-month extension options exercisable by the company to push the maturity to October 2030. The existing $350M term loan is split into three tranches: a $100M term loan maturing October 2029, a $100M term loan maturing October 2030, and a $150M term loan maturing April 2031. The amendment also removes a prior 0.10% (10 basis point) SOFR credit spread adjustment on all facility borrowings.
Global Medical REIT Inc. approved and implemented a one-for-five reverse stock split of its common stock. Effective as of 5:00 p.m. Eastern Time on September 19, 2025, every five shares of issued and outstanding common stock were converted into one share.
The reverse split temporarily changed the par value of common stock from $0.001 to $0.005 per share at the effective time, then immediately reverted it back to $0.001 per share. Authorized common shares were proportionately reduced from 500,000,000 to 100,000,000, while the 10,000,000 authorized preferred shares and their par value were unchanged.
The common stock will begin trading on a reverse split-adjusted basis on the NYSE on September 22, 2025, continuing under the symbol GMRE with a new CUSIP. Fractional share interests will be paid in cash based on the September 19, 2025 NYSE closing price, and all record holders are affected uniformly aside from minor changes from eliminating fractions. Equity plan share limits, outstanding awards, and related price-based performance metrics were adjusted proportionately.
Global Medical REIT Inc. director Matthew Cypher purchased 1,350 shares of the company's common stock on 08/26/2025 at a price of $7.3781 per share. After the transaction he beneficially owns 1,350 shares, held directly. The Form 4 was signed by an attorney-in-fact, Jamie Barber, on the same date.
Jamie Allen Barber, who serves as General Counsel and Secretary and is identified as a director, reported the sale of 130,000 shares of Global Medical REIT Inc. (GMRE) on 08/15/2025. The Form 4 shows the shares were sold at a weighted average price of $6.6236 (individual trade prices ranged from $6.50 to $6.74). Following the reported transactions the filing indicates 0 shares beneficially owned by the reporting person. The form was signed on 08/18/2025 and was filed by one reporting person.
Global Medical REIT Inc. (GMRE) director and CEO Mark O. Decker Jr. reported purchases of common stock on 08/15/2025: 13,871 shares at $6.84 (direct), and 17,023 shares at $6.87 (indirect via spouse). After these transactions he beneficially owned 173,871 shares directly and 190,894 shares indirectly.
Global Medical REIT Inc. (GMRE) Form 144: This notice reports a proposed sale of 130,000 common shares, with an aggregate market value of $878,000.00. The shares were acquired on 08/07/2025 as a stock award from the issuer and paid as compensation. The filer lists Fidelity Brokerage Services LLC (245 Summer Street, Boston MA) as the broker and identifies an approximate sale date of 08/15/2025 on the NYSE. The issuer's reported number of shares outstanding is 66,878,728. The filing states there were no securities sold in the past three months by the person for whose account the securities will be sold. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Jamie Barber, who serves as General Counsel and Secretary and is a director of Global Medical REIT Inc. (GMRE), converted 130,000 long-term incentive plan units (LTIP Units) in the operating partnership into OP Units and had those OP Units redeemed for an equal number of the issuer's common shares. As a result, Barber directly beneficially owns 130,000 shares of GMRE common stock following the transaction. The filing states LTIP Units were issued under the 2016 Equity Incentive Plan and have no expiration date, and OP Units may be redeemed for cash or, at the issuer's election, for one-for-one shares of common stock.
GMRE’s Q2 2025 10-Q shows modest top-line growth offset by higher financing costs. Rental revenue rose 10.7% YoY to $37.9 m, lifting total revenue to $38.0 m. Operating expense inflation (+13%) and an 15% jump in interest expense limited operating income to $0.4 m (vs. $1.4 m LY). Net income turned positive at $0.6 m, yet after $1.5 m preferred dividends common shareholders posted a $0.8 m loss (-$0.01/sh).
Balance sheet leverage increased. Net real-estate investment grew $42 m to $1.20 b after acquiring five facilities for $79.7 m and selling three for $9.1 m gains. Credit-facility borrowings expanded $67 m to $699 m, pushing total liabilities to $772 m (+10%). Equity fell 6% to $525 m, driven by dividend distributions and an $8.2 m OCI hit from falling swap values. Cash flow from operations covered common and preferred dividends ($34.4 m OCF vs. $33.4 m payouts). Management flags $24.6 m of committed cap-ex (≈$12.6 m in next 12 mo).
Key trends: 1) revenue growth from acquisitions continues; 2) elevated debt and rising SOFR expose earnings to rate risk despite hedges; 3) dividend remains higher than GAAP earnings but covered by FFO proxy cash flow; 4) active capital recycling—three small Q1-Q2 sales and a 12.5% JV stake launched in late-2024.